UNSPSC 51402302: Enciprazine

This classification denotes an anxiolytic with the molecular formula C23H32N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, L6X660925G chemically known as (+/-)-1-(3-(3,4,5-trimethoxyphenoxy)-2-hydroxypropyl)-4-(2-methoxyphenyl)piperazine but generally known as enciprazine, which bears US NIH Compound Identifier 50222. European Medicines Agency schedules Enciprazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06520MIG.

UNSPSC 51402302 Enciprazine is a Commodity code nominally designating a specific pharmaceutical compound, but recent state and local solicitation activity under this code shows minimal substantive alignment with the code's stated scope. The three recent opportunities posted under or associated with this code—a Seminole County naloxone and drug deactivation system procurement (IFB), a Texas Health and Human Services Commission direct-to-manufacturer prescription program RFI, and a Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) generic pharmaceuticals and over-the-counter products RFP—involve naloxone, broader pharmaceutical supply chains, and OTC products rather than enciprazine specifically. The mismatch suggests either systematic miscoding in state and local procurement systems or that this UNSPSC designation is being used as a catch-all for pharmaceutical and pharmaceutical-adjacent commodities at the point of solicitation entry. Issuing bodies include county public health authorities (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing consortia (MMCAP, administered through the Minnesota Department of Administration). The work solicited ranges from acute-response pharmaceutical commodities (naloxone) to wholesale distribution networks for generic and OTC medications serving state and local healthcare systems.

Geographic activity centers on Florida, Texas, and the Upper Midwest (Minnesota and participating MMCAP member states including Oregon). The most recent opportunities include Seminole County's IFB (posted June 30, 2026; due July 26, 2023—note the inconsistent date stamps in source records) seeking 1,900 annual units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the Texas HHS Commission's RFI (posted April 3, 2026; response due April 3, 2026) soliciting vendor capabilities for direct-to-manufacturer prescription relationships outside traditional pharmacy benefit manager and wholesale channels; and MMCAP's RFP (posted January 20, 2026; due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson wholesalers, with contract effectiveness targeted for July 1, 2026. No single issuing body appears twice in the recent record, and the code shows little relevant recent activity specific to enciprazine as a named pharmaceutical.